Conference Coverage
Conference Coverage
Hitting BTK, PI3K pays off in B-cell malignancies
Umbralisib, a second-generation PI3K inhibitor, appears to have a better safety profile than the first-in-class agent idelalisib.
Conference Coverage
NOTCH1 mutation predicts reduced ofatumumab efficacy in CLL
NEW YORK – Consider CLL patients with NOTCH1 gene mutation for chemotherapy “without type1 CD20 antibodies or a treatment with novel compounds.”...
Conference Coverage
iFCG achieves high MRD-negative remission in untreated CLL
NEW YORK – Could a three-course regimen for CLL have a positive affect on treatment?
Conference Coverage
ECG finding predicts AFib in ibrutinib-treated CLL
NEW YORK – Left atrial abnormality as measured by electrocardiogram in ibrutinib-treated patients with chronic lymphocytic leukemia can identify...
Conference Coverage
In good-candidate CLL, don’t wait too long for alloHCT
NEW YORK – Allogeneic hematopoietic stem cell transplantation (alloHCT) using HLA-compatible donors results in excellent long-term progression-...
Conference Coverage
Ibrutinib response in CLL/SLL less affected by select risk factors
NEW YORK – Risk factors associated with poor outcomes in chronic lymphocytic leukemia/small lymphocytic leukemia patients treated with standard...
Conference Coverage
Early allo SCT advised for high-risk mantle cell lymphoma
High-risk patients with mantle cell lymphoma who have a matched related donor have a better chance for survival if they do not delay allogeneic...
Conference Coverage
ALC/AMC prognostic in mantle cell lymphoma
The peripheral blood absolute lymphocyte-to-monocyte ratio (ALC/AMC) was prognostic for overall survival in mantle cell lymphoma patients who have...
Conference Coverage
In mantle cell lymphoma, triple therapy proves too toxic
Combined idelalisib, lenalidomide, and rituximab proved excessively toxic for the treatment of relapsed and refractory mantle cell and follicular...
Conference Coverage
Targeted drugs transform CLL management
NEW YORK – Patients with CLL are living longer, creating new challenges in long-term care.